Interactions between disseminated tumor cells (DTCs) and stromal cells in the microenvironment are critical for tumor colonization of distal organs. Recent studies have shown that vascular cell adhesion molecule-1 (VCAM-1) is aberrantly expressed in breast cancer cells and mediates pro-metastatic tumor-stromal interactions. Moreover, the usefulness of VCAM-1 to DTCs in two different organs -lung and bone-is based on distinct mechanisms. In the lungs, VCAM-1 on the surface of cancer cells binds to its counter-receptor, the α4β1 integrin (also known as very-late antigen, VLA-4), on metastasis-associated macrophages, triggering VCAM-1 mediated activation of the PI3K growth and survival pathway in the cancer cells. In the bone marrow, cancer cell VCAM-1 attracts and tethers α4 integrin-expressing osteoclast progenitors to facilitate their maturation into multinucleated osteoclasts that mediate osteolytic metastasis. 
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Background
Over the last several decades, early detection, surgical removal and targeted therapy have improved treatment outcome for primary breast tumors. However, breast cancer still has a high mortality rate which is primarily due to metastatic disease. Lung, bone, brain and liver are the most common sites of distant dissemination (1, 2) . Metastasis from primary sites to distal organs is a complex process that involves a series of sequential steps: invasion and intravasation of tumor cells from the primary tumor sites to enter the circulation, extravasation of these circulating tumor cells (CTCs) into distant tissues, and final colonization of the seeded organ (3, 4) . Even though CTCs are present in large numbers in the bloodstream, only a small proportion of these cells succeed in forming distal metastasis (1, 5) . As envisioned in the 'seed and soil' hypothesis (6, 7) , the organ tropism of metastasis depends on the complex interplay between tumor cells and the unique microenvironments of different distal organs. The underlying mechanisms of this interplay are just beginning to be elucidated. Two recent studies on a cell surface molecule that mediate cell adhesion, termed vascular cell adhesion molecule-1 (VCAM-1), provide new insights into these mechanisms. When aberrantly expressed in breast cancer cells, VCAM-1 mediates distinct tumor-stromal interactions that are unique to lung and bone microenvironments and facilitate metastasis to these sites (8, 9) . Little is known about the function of VCAM-1 in other cancers. However, VCAM-1 expression has been reported in gastric and renal carcinomas, and melanomas (10) (11) (12) , where it might plays roles similar to those recently reported in breast cancer (8, 9) . The new work identifies VCAM-1 as an interesting new player in tumor progression and a target worth considering for potential therapies against lung and bone metastasis of breast cancer and other cancers.
VCAM-1 as an adhesion molecule in endothelial cells
VCAM-1 is an immunoglobulin (Ig)-like adhesion molecule with seven extracellular Ig domains that are mainly expressed in endothelial cells (13, 14) . While expressed at low level on resting endothelial cells, VCAM-1 is strongly induced by several inflammatory cytokines (15, 16) .
VCAM-1 binds with high affinity to the integrins α4β1 (also known as very-late antigen, VLA-4) and α4β7. α4β1 in particular is a well-studied counter-receptor expressed on the surface of several cell types of the hematopotietic lineage including lymphocytes, monocyte/macrophages and eosinophils (17) . VCAM-1 plays a critical role in the inflammatory response by recruiting leukocytes to acute and chronic inflammatory sites (15, 16 passage from blood to tissue. The short intracellular tail of VCAM-1 interacts with Ezrin (also known as cytovillin or villin-2), a member of the ERM (Ezrin/Radixin/Moesin) protein family (18) .
ERM are cytoplasmic adaptor proteins that link various transmembrane proteins to the actin cytoskeleton (18) . In endothelial cells, VCAM-1 clustering, either by antibody cross-linking or integrin binding, triggers the activation of Rac1, which is a Rho-like GTPase (19) . The activation of Rac1 results in the rearrangement of the cytoskeletal network, which is thought to remodel the tight junctions between vascular endothelial cells and consequently facilitate transendothelial migration. Circulating melanoma cells expressing α4 integrin have been shown to interact with VCAM-1 on endothelial cells to facilitate extravasation and metastasis in distal organs (20) (21) (22) . Therefore, in addition to passive entrapment of tumor cells by size restriction (4), capillary beds may actively participate in the extravasation into disseminated sites of CTCs via the adhesion molecules on vascular endothelial cells.
Role of VCAM-1 in lung metastasis of breast cancer
Studies combining animal models and analyses of clinical samples identified a lung metastatic gene signature (LMS) as a set of 18 genes whose expression is associated with lung relapse in estrogen receptor-negative (ER-) tumors and mediates lung metastasis in xenograft models (23) .
Understanding the molecular mechanisms of how the LMS genes mediate lung metastasis can provide novel treatment modalities for lung metastasis of breast cancer. VCAM-1 is among these 18 genes, and its expression in breast cancer cells enhances the ability to form metastases in the lungs (8, 23) 
Clinical-Translational Advances
The prevention and treatment of metastatic breast cancer remain a challenge. The recent findings on the roles of VCAM-1 in lung and bone metastasis provide one potential target to control the disease. Drugs that disrupt the binding of α4 intergrins to VCAM-1 have already been in development to treat diseases involving massive influx of leukocytes into inflammatory sites (31, 32) . Natalizumab, a monoclonal antibody against α4 integrin, is an FDA-approved drug for the treatment of relapsing multiple sclerosis (MS) and inflammatory bowel disease and increase the half-life of the drug in patients (33, 34) . Its efficacy in treating MS was preclinically demonstrated using an animal model of autoimmune encephalomyelitis (EAE) (35) .
Cerebral microvessels in these animals, as well as in MS patients, display high VCAM-1 expression prior to perivascular leukocyte infiltration (36) . AN100226m suppressed and reversed the disease progression in the EAE animal model (37) . Natalizumab can block α4 integrin binding to both MAdCAM-1 and VCAM-1, the two adhesion molecules mediating leukocyte trafficking in gut-associated lymphoid organs and inflammatory sites (15, 38, 39) .
According to the public accessible website from U.S. National Institute of Health (ClinicalTrials.gov), Biogen Idec additionally conducted a clinical trial testing the utility of natalizumab as a potential therapy for multiple myeloma (MM) (40) . In animal models of MM, anti-α4 integrin treatment decreases the growth of MM in bone marrow (41) (42) (43) . This suppressive effect is due to the disruption of α4 integrin interactions between tumor and bone marrow stromal cells as well as tumor cells and extracellular matrix proteins (43) (44) (45) (46) (47) .
Although no significant adverse events were observed in earlier clinical trial studies of natanizumab, a small proportion of patients developed progressive multifocal leukoencephalopathy (48) . This is a rare but fatal neurological condition that occurs in patients with severe immune deficient condition (49) . Therefore, Natalizumab is not approved in combination with immunossupressive agents. Immunosuppression is a common adverse effect of many chemotherapeutic agents used to treat breast cancer, creating a significant challenge for the potential use of natalizumab to treat metastatic breast cancer.
Small molecule inhibitors against α4 integrin
Small molecule inhibitors against a4 integrin have been developed, largely by structure based design. They are in clinical testing for its efficacy in treating autoimmune diseases, but still in much more preliminary stage than antibody based therapy. Importantly, these small molecules have several advantages over antibody based therapy. Although the human IgG 4 framework used to humanize natalizumab does not activate the complement cascade and has low affinity to Fc receptors, antibodies against natalizumab still emerged in 11% of MS patients and 7% of IBD patients in the clinical trials (50, 51) . This problem is largely averted with small molecules.
Furthermore, long-term treatment is required for autoimmune diseases and potentially in breast cancer patients to with metastasis. Natalizumab needs to be administered intravenously over one hour every four weeks, whereas small molecule inhibitors of α4 integrin make oral bioavailability possible (52) . Despite these advantages over Natalizumab, the application of 
